[1]
M. Komorowski, L. A. Celi, O. Badawi, A. C. Gordon, and A. A. Faisal, ‘The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care’, Nature Medicine, vol. 24, no. 11, pp. 1716–1720, Nov. 2018, doi: 10.1038/s41591-018-0213-5.
[2]
D. McPherson et al., ‘Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010’, BMJ Open, vol. 3, no. 8, Aug. 2013, doi: 10.1136/bmjopen-2013-002586.
[3]
D. C. Norman, ‘Fever in the Elderly’, Clinical Infectious Diseases, vol. 31, no. 1, pp. 148–151, Jul. 2000, doi: 10.1086/313896.
[4]
‘Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour: Results From a Guideline-Based Performance Improvement Program* | Ovid’, 2014. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003246&LSLINK=80&D=jbi
[5]
L. Evans, ‘A Closer Look at Sepsis-Associated Mortality’, JAMA Network Open, vol. 2, no. 2, Feb. 2019, doi: 10.1001/jamanetworkopen.2018.7565.
[6]
D. De Backer and T. Dorman, ‘Surviving Sepsis Guidelines’, JAMA, vol. 317, no. 8, Feb. 2017, doi: 10.1001/jama.2017.0059.
[7]
M. Sund-Levander, C. Forsberg, and L. K. Wahren, ‘Normal oral, rectal, tympanic and axillary body temperature in adult men and women: a systematic literature review’, Scandinavian Journal of Caring Sciences, vol. 16, no. 2, pp. 122–128, Jun. 2002, doi: 10.1046/j.1471-6712.2002.00069.x.
[8]
C. Rhee et al., ‘Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals’, JAMA Network Open, vol. 2, no. 2, Feb. 2019, doi: 10.1001/jamanetworkopen.2018.7571.
[9]
M. Singer et al., ‘The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)’, JAMA, vol. 315, no. 8, Feb. 2016, doi: 10.1001/jama.2016.0287.
[10]
M. D. Howell and A. M. Davis, ‘Management of Sepsis and Septic Shock’, JAMA, vol. 317, no. 8, Feb. 2017, doi: 10.1001/jama.2017.0131.
[11]
C. W. Seymour et al., ‘Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis’, JAMA, vol. 321, no. 20, May 2019, doi: 10.1001/jama.2019.5791.
[12]
W. A. Knaus and R. D. Marks, ‘New Phenotypes for Sepsis’, JAMA, vol. 321, no. 20, May 2019, doi: 10.1001/jama.2019.5794.
[13]
S. Zhou et al., ‘miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges’, Acta Pharmacologica Sinica, vol. 39, no. 7, pp. 1073–1084, Jul. 2018, doi: 10.1038/aps.2018.30.
[14]
‘Circulation Research’, [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/01.RES.0000252802.25497.b7
[15]
‘Circulation Research’, [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.116.309692
[16]
G. Wick and C. Grundtman, Eds., Inflammation and Atherosclerosis. Vienna: Springer Vienna, 2012. doi: 10.1007/978-3-7091-0338-8.
[17]
P. C. Westman et al., ‘Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction’, Journal of the American College of Cardiology, vol. 67, no. 17, pp. 2050–2060, May 2016, doi: 10.1016/j.jacc.2016.01.073.
[18]
N. G. Frangogiannis, ‘Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities’, Molecular Aspects of Medicine, vol. 65, pp. 70–99, Feb. 2019, doi: 10.1016/j.mam.2018.07.001.
[19]
‘Circulation Research’, [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.116.308537
[20]
‘Arteriosclerosis, Thrombosis, and Vascular Biology’, [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.119.311996?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
[21]
A. Hafiane and S. S. Daskalopoulou, ‘Extracellular vesicles characteristics and emerging roles in atherosclerotic cardiovascular disease’, Metabolism, vol. 85, pp. 213–222, Aug. 2018, doi: 10.1016/j.metabol.2018.04.008.
[22]
‘Circulation Research’, [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.117.312465
[23]
S. Huang and N. G. Frangogiannis, ‘Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges’, British Journal of Pharmacology, vol. 175, no. 9, pp. 1377–1400, May 2018, doi: 10.1111/bph.14155.
[24]
‘Arteriosclerosis, Thrombosis, and Vascular Biology’, [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.110.207480